Scientific publications

Hyperbilirubinemia and retinopathy of prematurity: a retrospective cohort study. Scientific Publication

Jun 15, 2024 | Magazine: European Journal of Pediatrics

Silvia Gulden #  1 , Gaia Cervellini #  2   3 , Marta Colombo  1 , Maria Beatrice Marangoni  2   3 , Vittoria Taccani  2   3 , Nicola Pesenti  2   4 , Genny Raffaeli  5   6 , Gabriella Araimo  2 , Silvia Osnaghi  7 , Monica Fumagalli  2   3 , Felipe Garrido  8 , Eduardo Villamor #  9 , Giacomo Cavallaro #  2


Abstract

Retinopathy of prematurity (ROP) is a vasoproliferative retinal disease in preterm infants. Oxidative stress plays a key role in the pathogenesis of ROP. Due to its antioxidant effects, bilirubin has been proposed to be protective against ROP. This study explored the association between hyperbilirubinemia and ROP.

We analyzed a 10-year cohort from a neonatal intensive care unit in Milan, Italy, including 1606 infants born under 32 weeks and/or < 1500 g. Data from 1606 infants meeting specific inclusion criteria were reviewed. Eighty infants were excluded due to lack of data, 1526 were deemed eligible for analysis, and 1269 had hyperbilirubinemia requiring phototherapy. There was a higher incidence of ROP among infants with hyperbilirubinemia (13.8%) versus those without (7.8%, p<0.01).

Infants with any ROP, non-severe or severe ROP, were exposed to hyperbilirubinemia for a significantly higher number of days compared with those without ROP. Each additional day of exposure increases the risk of developing any ROP by 5%, non-severe ROP by 4%, and severe ROP by 6%. However, this correlation was not observed in infants with gestational age less than 27 weeks and/or body weight less than 1000 g.

Conclusion: Our data show that hyperbilirubinemia requiring phototherapy is associated with an increased risk of developing ROP. However, severe hyperbilirubinemia and ROP share many of their risk factors. Therefore, rather than being a risk factor itself, hyperbilirubinemia may be a surrogate for other risk factors for ROP.

Clinical Trial Registration: NCT05806684.

What is Known:

  • The development of retinopathy of prematurity (ROP) is influenced by several critical risk factors, including low gestational age, low birth weight, supplemental oxygen use, and increased oxidative stress.
  • In vitro, unconjugated bilirubin is an effective scavenger of harmful oxygen species and a reducing agent, highlighting its potential protective role against oxidative stress.

What is New:

  • Hyperbilirubinemia requiring phototherapy was associated with an increased risk of developing ROP, but this association was not observed in the most vulnerable population of extremely preterm infants.
  • Every additional day of phototherapy for hyperbilirubinemia increases the risk of ROP by 5% for any ROP, 4% for non-severe ROP, and 6% for severe ROP.

CITATION  Eur J Pediatr. 2024 Jun 15.  doi: 10.1007/s00431-024-05630-3